Health Score

0 Fair

Metadata coverage

Abstract

ORCID

References

License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder

Award / grant

Affiliation & institutional identifiers

Affiliation

ROR ID

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

Attach ORCID iDs across 2269 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

High impact2269 DOIs

Deposit reference lists for 1738 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

High impact1738 DOIs

Add abstracts to 338 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

Low impact338 DOIs

DOIs for this ISSN

Showing the top 5 of 2391 DOIs, ordered by correction priority.

#	Title	Missing	Priority	Citations
1	The Role of Cutaneous Microbiota Harmony in Maintaining a Fu… (10.25251/skin.1.supp.138)	References ORCID	69.01	23
2	Adjuvant therapy with nivolumab versus placebo in patients w… (10.25251/skin.7.supp.163)	References ORCID	69.01	23
3	Secukinumab in Moderate to Severe Hidradenitis Suppurativa:… (10.25251/skin.7.supp.129)	Abstract References ORCID	63.38	6
4	Bimekizumab Impact on Pain in Moderate to Severe Hidradeniti… (10.25251/skin.8.supp.350)	Abstract References ORCID	63.38	6
5	Global Burden of Skin and Subcutaneous Disease: A Longitudin… (10.25251/skin.5.2.7)	References ORCID	61.52	16
6	A Machine Learning-Based Test for Predicting Response to Pso… (10.25251/skin.5.6.5)	References ORCID	61.52	16
7	Non-Invasive Detection of Genomic Atypia Increases Real-Worl… (10.25251/skin.5.5.9)	References ORCID	58.80	14
8	Tapinarof Inhibits the Formation, Cytokine Production, and P… (10.25251/skin.7.supp.194)	Abstract References ORCID	58.36	5
9	A Phase 2b Dose-Ranging Efficacy and Safety Study of Traloki… (10.25251/skin.2.supp.28)	References ORCID	57.31	13
10	Integrating Electrical Impedance Spectroscopy into Clinical… (10.25251/skin.4.5.5)	References ORCID	53.96	11
11	Development and Validation of a Diagnostic 35-Gene Expressio… (10.25251/skin.4.6.3)	References ORCID	53.96	11
12	Successful Treatment of Morphea with Topical Ruxolitinib (10.25251/skin.7.2.19)	Abstract References ORCID	52.42	4
13	Integrated Safety Analysis of Ritlecitinib for the Treatment… (10.25251/skin.7.supp.291)	Abstract References ORCID	52.42	4
14	Non-invasive Gene Expression Analysis Rules Out Melanoma wit… (10.25251/skin.8.supp.384)	Abstract References ORCID	52.42	4
15	Tapinarof Cream 1% QD for the Treatment of Plaque Psoriasis:… (10.25251/skin.4.supp.75)	References ORCID	50.00	9
16	Efficacy and safety of tralokinumab in adolescents with mode… (10.25251/skin.6.supp.s29)	References ORCID	50.00	9
17	A Comprehensive Survey Assessing the Family Planning Needs o… (10.25251/skin.2.supp.90)	References ORCID	47.71	8
18	Maintenance of Response With Guselkumab for up to 3 Years’ T… (10.25251/skin.2.supp.91)	References ORCID	47.71	8
19	A Systematic Review and Meta-Analysis of Gene Expression Pro… (10.25251/skin.4.3.3)	References ORCID	47.71	8
20	Efficacy and Safety of Ruxolitinib Cream for the Treatment o… (10.25251/skin.4.supp.95)	References ORCID	47.71	8
21	Deucravacitinib long-term efficacy and safety in plaque psor… (10.25251/skin.6.supp.48)	References ORCID	47.71	8
22	Genomic Atypia to Enrich Melanoma Positivity in Biopsied Les… (10.25251/skin.5.1.3)	References ORCID	45.15	7
23	Impact of Disease History on the Efficacy of Ritlecitinib (P… (10.25251/skin.6.supp.101)	Abstract References ORCID	45.15	3
24	Xylazine: An Ulcerating Addiction (10.25251/skin.7.4.24)	Abstract References ORCID	45.15	3
25	Phase 2 study of cemiplimab in patients with advanced cutane… (10.25251/skin.7.supp.176)	Abstract References ORCID	45.15	3
26	Gene Expression Differences Identified in Skin Samples of Ea… (10.25251/skin.7.supp.267)	Abstract References ORCID	45.15	3
27	Efficacy and Safety of Lebrikizumab Is Maintained to Two Yea… (10.25251/skin.7.supp.271)	Abstract References ORCID	45.15	3
28	APG777, a Humanized IgG1 Monoclonal Antibody, Binds to IL-13… (10.25251/skin.8.supp.314)	Abstract References ORCID	45.15	3
29	Bimekizumab Efficacy by Prior Biologic Treatment in Patients… (10.25251/skin.8.supp.349)	Abstract References ORCID	45.15	3
30	Bimekizumab for the Treatment of Moderate to Severe Plaque P… (10.25251/skin.5.supp.18)	References ORCID	42.25	6
31	Once-Daily Roflumilast Cream 0.3%, a Potent Phosphodiesteras… (10.25251/skin.5.supp.42)	References ORCID	42.25	6
32	Spesolimab for Hidradenitis Suppurativa: A Proof-of-Concept… (10.25251/skin.7.supp.286)	References ORCID	42.25	6
33	Long-Term Efficacy of Ritlecitinib up to Month 24 From the A… (10.25251/skin.8.supp.394)	References ORCID	42.25	6
34	Lebrikizumab Improves Atopic Dermatitis and Quality of Life… (10.25251/skin.9.supp.512)	References ORCID	42.25	6
35	Efficacy and Safety of Apremilast in Patients with Moderate… (10.25251/skin.1.supp.10)	References ORCID	38.91	5
36	A Randomized Vehicle-Controlled Trial to Assess the Efficacy… (10.25251/skin.1.supp.102)	References ORCID	38.91	5
37	BMS-986165, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhi… (10.25251/skin.4.supp.28)	References ORCID	38.91	5
38	Efficacy and Safety of Tralokinumab Monotherapy in Adult Pat… (10.25251/skin.4.supp.96)	References ORCID	38.91	5
39	A Case of Granulomatous Hypersensitivity Reactions to a Derm… (10.25251/skin.5.1.10)	References ORCID	38.91	5
40	Adaptations of Dermatology Residency Programs to Changes in… (10.25251/skin.5.2.3)	References ORCID	38.91	5
41	Economic Evaluation of The Budget Impact of Precision Medici… (10.25251/skin.5.4.6)	References ORCID	38.91	5
42	Safety of Specifically Targeting Interleukin 13 with Traloki… (10.25251/skin.5.supp.11)	References ORCID	38.91	5
43	Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2)… (10.25251/skin.5.supp.37)	References ORCID	38.91	5
44	Primary Analysis of Phase 2 Results for Cemiplimab in Patien… (10.25251/skin.5.supp.4)	References ORCID	38.91	5
45	A Review of the Risk of Cutaneous Squamous Cell Carcinoma af… (10.25251/skin.6.6.1)	References ORCID	38.91	5
46	The Integrated 31-Gene Expression Profile (i31-GEP) Test for… (10.25251/skin.6.6.3)	References ORCID	38.91	5
47	A Prospective, Multi-Center Clinical Utility Study Demonstra… (10.25251/skin.6.6.5)	References ORCID	38.91	5
48	Sunscreen Knowledge and Sun Protective Behaviors among Medic… (10.25251/skin.7.2.3)	References ORCID	38.91	5
49	Clinician- and Patient-Reported Outcomes with Tirbanibulin 1… (10.25251/skin.7.3.3)	References ORCID	38.91	5
50	Prospective, Multicenter Clinical Impact Evaluation of a 31-… (10.25251/skin.2.2.3)	ORCID	36.93	29